Current Report Filing (8-k)
September 05 2018 - 11:35AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 5, 2018
Trovagene, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-35558
|
|
27-2004382
|
(State or other jurisdiction of
incorporation or organization)
|
|
(Commission
File Number)
|
|
IRS Employer
Identification No.)
|
11055 Flintkote Avenue
San Diego, CA 92121
(Address of principal executive offices)
Registrants telephone number, including area code: (858)
952-7570
(Former name or former address, if changed since last report)
Check the appropriate box below if the
Form 8-K
filing is intended to simultaneously satisfy the filing
obligation of the registrant under any of the following provisions:
☐
|
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to
Rule 14a-12
under the Exchange Act
(17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to
Rule 14d-2(b) under
the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to
Rule 13e-4(c) under
the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or
Rule 12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter). Emerging growth
company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
On September 5, 2018, Trovagene, Inc. issued a press release announcing it has developed a method for predicting response to
treatment by measuring the ability of Onvansertib, a
first-in-class,
3
rd
generation, oral and highly-selective
Polo-like Kinase 1 (PLK1 ), to inhibit PLK1 in patients with Acute Myeloid Leukemia (AML). A copy of the press release is furnished as Exhibit 99.1 to this
Form 8-K.
Item 9.01. Financial Statements and Exhibits
(d)
Exhibits.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Dated: September 5, 2018
|
|
|
TROVAGENE, INC.
|
|
|
By:
|
|
/s/ Thomas Adams
|
|
|
Thomas Adams
|
|
|
Interim Chief Executive Officer
|
-2-
Cardiff Oncology (NASDAQ:CRDF)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cardiff Oncology (NASDAQ:CRDF)
Historical Stock Chart
From Apr 2023 to Apr 2024